^
Association details:
| Biomarker: | POLE mutation |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Investigating the various predictive values of POLE/POLD1 mutations for response to immune checkpoint inhibitors (ICIs) in different solid tumors.
Published date:
05/19/2021
Excerpt:
...we found the associations of POLE/POLD1 mutations with longer median OS in NSCLC (Undefined vs 12.00 months, P = 0.05) and esophagogastric cancer (27.00 vs 15.00 months, P = 0.05).
DOI:
10.1200/JCO.2021.39.15_suppl.2606
